Armed antibodies for cancer treatment

a promising tool in a changing era

Riccardo Danielli, Roberto Patuzzo, Pier A delchi Ruffini, Andrea Maurichi, Leonardo Giovannoni, Giuliano Elia, Dario Neri, Mario Santinami

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Advances in the understanding of tumor immunology and molecular biology of melanoma cells have favored a larger application of immunotherapy and targeted therapies in the clinic. Several selective mutant gene inhibitors and immunomodulating antibodies have been reported to improve overall survival or progression-free survival in metastatic melanoma patients. However, despite impressive initial responses, patients treated with selective inhibitors relapse quickly, and toxicities associated to the use of immunomodulating antibodies are not easily manageable. In this sense, the concept of using antibodies as delivery vehicles for the preferential in vivo localization of the drug at the site of disease with reduction of side effects has raised particular interest. Antibody-cytokine fusion proteins (termed immunocytokines) represent a new simple and effective way to deliver the immunomodulatory payload at the tumor site, with the aim of inducing both local and systemic antitumoral immune responses and limiting systemic toxicities. Several clinical trials have been conducted and are actually ongoing with different immunocytokines, in several tumor histotypes. In metastatic melanoma patients, different drug delivery modalities such as systemic, loco-regional and intratumoral are under investigation. In this review, the rationale for the use of L19-IL2 and L19-TNF, two clinical stage immunocytokines produced by the Philogen group, as well as opportunities for their future development will be discussed.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume64
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Melanoma
Antibodies
Neoplasms
Therapeutics
Allergy and Immunology
Pharmaceutical Preparations
Immunotherapy
Disease-Free Survival
Interleukin-2
Molecular Biology
Clinical Trials
Cytokines
Recurrence
Survival
Genes
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Armed antibodies for cancer treatment : a promising tool in a changing era. / Danielli, Riccardo; Patuzzo, Roberto; Ruffini, Pier A delchi; Maurichi, Andrea; Giovannoni, Leonardo; Elia, Giuliano; Neri, Dario; Santinami, Mario.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 1, 01.01.2015, p. 113-121.

Research output: Contribution to journalArticle

Danielli, Riccardo ; Patuzzo, Roberto ; Ruffini, Pier A delchi ; Maurichi, Andrea ; Giovannoni, Leonardo ; Elia, Giuliano ; Neri, Dario ; Santinami, Mario. / Armed antibodies for cancer treatment : a promising tool in a changing era. In: Cancer Immunology, Immunotherapy. 2015 ; Vol. 64, No. 1. pp. 113-121.
@article{833617a29a8e4b689992ce0bf3c47289,
title = "Armed antibodies for cancer treatment: a promising tool in a changing era",
abstract = "Advances in the understanding of tumor immunology and molecular biology of melanoma cells have favored a larger application of immunotherapy and targeted therapies in the clinic. Several selective mutant gene inhibitors and immunomodulating antibodies have been reported to improve overall survival or progression-free survival in metastatic melanoma patients. However, despite impressive initial responses, patients treated with selective inhibitors relapse quickly, and toxicities associated to the use of immunomodulating antibodies are not easily manageable. In this sense, the concept of using antibodies as delivery vehicles for the preferential in vivo localization of the drug at the site of disease with reduction of side effects has raised particular interest. Antibody-cytokine fusion proteins (termed immunocytokines) represent a new simple and effective way to deliver the immunomodulatory payload at the tumor site, with the aim of inducing both local and systemic antitumoral immune responses and limiting systemic toxicities. Several clinical trials have been conducted and are actually ongoing with different immunocytokines, in several tumor histotypes. In metastatic melanoma patients, different drug delivery modalities such as systemic, loco-regional and intratumoral are under investigation. In this review, the rationale for the use of L19-IL2 and L19-TNF, two clinical stage immunocytokines produced by the Philogen group, as well as opportunities for their future development will be discussed.",
author = "Riccardo Danielli and Roberto Patuzzo and Ruffini, {Pier A delchi} and Andrea Maurichi and Leonardo Giovannoni and Giuliano Elia and Dario Neri and Mario Santinami",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1621-0",
language = "English",
volume = "64",
pages = "113--121",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Armed antibodies for cancer treatment

T2 - a promising tool in a changing era

AU - Danielli, Riccardo

AU - Patuzzo, Roberto

AU - Ruffini, Pier A delchi

AU - Maurichi, Andrea

AU - Giovannoni, Leonardo

AU - Elia, Giuliano

AU - Neri, Dario

AU - Santinami, Mario

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Advances in the understanding of tumor immunology and molecular biology of melanoma cells have favored a larger application of immunotherapy and targeted therapies in the clinic. Several selective mutant gene inhibitors and immunomodulating antibodies have been reported to improve overall survival or progression-free survival in metastatic melanoma patients. However, despite impressive initial responses, patients treated with selective inhibitors relapse quickly, and toxicities associated to the use of immunomodulating antibodies are not easily manageable. In this sense, the concept of using antibodies as delivery vehicles for the preferential in vivo localization of the drug at the site of disease with reduction of side effects has raised particular interest. Antibody-cytokine fusion proteins (termed immunocytokines) represent a new simple and effective way to deliver the immunomodulatory payload at the tumor site, with the aim of inducing both local and systemic antitumoral immune responses and limiting systemic toxicities. Several clinical trials have been conducted and are actually ongoing with different immunocytokines, in several tumor histotypes. In metastatic melanoma patients, different drug delivery modalities such as systemic, loco-regional and intratumoral are under investigation. In this review, the rationale for the use of L19-IL2 and L19-TNF, two clinical stage immunocytokines produced by the Philogen group, as well as opportunities for their future development will be discussed.

AB - Advances in the understanding of tumor immunology and molecular biology of melanoma cells have favored a larger application of immunotherapy and targeted therapies in the clinic. Several selective mutant gene inhibitors and immunomodulating antibodies have been reported to improve overall survival or progression-free survival in metastatic melanoma patients. However, despite impressive initial responses, patients treated with selective inhibitors relapse quickly, and toxicities associated to the use of immunomodulating antibodies are not easily manageable. In this sense, the concept of using antibodies as delivery vehicles for the preferential in vivo localization of the drug at the site of disease with reduction of side effects has raised particular interest. Antibody-cytokine fusion proteins (termed immunocytokines) represent a new simple and effective way to deliver the immunomodulatory payload at the tumor site, with the aim of inducing both local and systemic antitumoral immune responses and limiting systemic toxicities. Several clinical trials have been conducted and are actually ongoing with different immunocytokines, in several tumor histotypes. In metastatic melanoma patients, different drug delivery modalities such as systemic, loco-regional and intratumoral are under investigation. In this review, the rationale for the use of L19-IL2 and L19-TNF, two clinical stage immunocytokines produced by the Philogen group, as well as opportunities for their future development will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84925028550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925028550&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1621-0

DO - 10.1007/s00262-014-1621-0

M3 - Article

VL - 64

SP - 113

EP - 121

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -